New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 27, 2014
09:09 EDTKERXKeryx could benefit from House bill, says JMP Securities
After reviewing language in the House doc fix bill, JMP Securities indicates that reimbursement for Keryx's Zerenex drug may not be cut 37.5% beginning in 2016, as the firm had previously expected. The bill indicates that the reduction may be delayed until 2024, according t o the firm which keeps an Outperform rating on the shares.
News For KERX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for KERX

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use